Protective effect of FTY720 against sevoflurane-induced developmental neurotoxicity in rats.
Zhou H, Li S, Niu X, Wang P, Wang J, Zhang M.
Cell Biochem Biophys · journal article · DOI 10.1007/s12013-013-9546-3 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fingolimod. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
30 hitsFTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Huu DL, Matsushita T, Jin G, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M.
Arthritis Rheum · research support, non-u.s. gov't; journal article · DOI 10.1002/art.37933Sphingosine 1-phosphate receptor agonists: a patent review (2010-2012).
Roberts E, Guerrero M, Urbano M, Rosen H.
Expert Opin Ther Pat · review; journal article · DOI 10.1517/13543776.2013.783022Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X.
Ophthalmology · clinical trial, phase iii; clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal article; case reports · DOI 10.1016/j.ophtha.2012.12.040Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A, Kihara Y, Chun J.
J Neurol Sci · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jns.2013.02.011Systematic review and meta-analysis of the efficacy of sphingosine-1-phosphate (S1P) receptor agonist FTY720 (fingolimod) in animal models of stroke.
Liu J, Zhang C, Tao W, Liu M.
Int J Neurosci · meta-analysis; research support, non-u.s. gov't; systematic review; journal article · DOI 10.3109/00207454.2012.749255Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage.
Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, Ostrowski R, Manaenko A, Tang J, Zhang JH.
Exp Neurol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.expneurol.2012.12.009Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden.
Bergvall N, Tambour M, Henriksson F, Fredrikson S.
J Med Econ · comparative study; research support, non-u.s. gov't; journal article · DOI 10.3111/13696998.2012.755537Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Nolan R, Gelfand JM, Green AJ.
Neurology · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1212/wnl.0b013e31827b9132The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice.
Bruce CR, Risis S, Babb JR, Yang C, Lee-Young RS, Henstridge DC, Febbraio MA.
Endocrinology · research support, non-u.s. gov't; journal article · DOI 10.1210/en.2012-1847Fingolimod protects cultured cortical neurons against excitotoxic death.
Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, Turrini R, Caraci F, Copani A, Battaglia G, Nicoletti F, Nicoletti F, Bruno V.
Pharmacol Res · journal article · DOI 10.1016/j.phrs.2012.10.004Insights into the pharmacological relevance of lysophospholipid receptors.
Mutoh T, Rivera R, Chun J.
Br J Pharmacol · review-article; review; journal article; research support, n.i.h., extramural · DOI 10.1111/j.1476-5381.2011.01622.x[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Winkelmann A, Löbermann M, Reisinger EC, Zettl UK.
Nervenarzt · journal article; english abstract · DOI 10.1007/s00115-011-3360-1Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Mehling M, Kappos L, Derfuss T.
Curr Neurol Neurosci Rep · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s11910-011-0216-9A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Chun J, Brinkmann V.
Discov Med · research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramuralDevelopment of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y, Milstien S, Spiegel S.
Pharmacol Ther · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1016/j.pharmthera.2011.08.004Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
Scott LJ.
CNS Drugs · review; journal article · DOI 10.2165/11207350-000000000-00000Delayed fingolimod-associated asystole.
Espinosa PS, Berger JR.
Mult Scler · journal article; case reports · DOI 10.1177/1352458511410344Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP.
Clin Immunol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.clim.2011.05.005Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR, Pearce CJ, Oberlies NH.
J Nat Prod · review; journal article · DOI 10.1021/np2000528Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D.
Mult Scler · research support, non-u.s. gov't; journal article · DOI 10.1177/1352458511400476Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA, Weinstock-Guttman B.
Adv Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s12325-011-0004-6Current disease-modifying treatment of multiple sclerosis.
Derwenskus J.
Mt Sinai J Med · review; journal article · DOI 10.1002/msj.20239BZM055, an iodinated radiotracer candidate for PET and SPECT imaging of myelin and FTY720 brain distribution.
Briard E, Orain D, Beerli C, Billich A, Streiff M, Bigaud M, Auberson YP.
ChemMedChem · journal article · DOI 10.1002/cmdc.201000477Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S.
Drug Metab Dispos · clinical trial; journal article · DOI 10.1124/dmd.110.035907CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Jin Y, Zollinger M, Borell H, Zimmerlin A, Patten CJ.
Drug Metab Dispos · journal article · DOI 10.1124/dmd.110.035378Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH.
Stroke · research-article; journal article; research support, n.i.h., extramural · DOI 10.1161/strokeaha.109.568899Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT, Fan ST.
Int J Oncol · research support, non-u.s. gov't; journal articleSphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
Paugh SW, Cassidy MP, He H, Milstien S, Sim-Selley LJ, Spiegel S, Selley DE.
Mol Pharmacol · comparative study; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.105.020552Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.
Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A, Katsuoka Y.
Cancer Res · journal article